|
|
|
|
|
Written Summaries by Clinicians for Clinicians from EAU24 starting Friday |
|
|
|
|
|
| Plenary Session: Controversies on GU Cancer Staging: Is It Only Imaging? - 8:00-10:00 AM
|
|
|
|
|
Disease Characterization: Advantages and Pitfalls of Molecular Imaging
Presented By: Ken Herrmann, MD
|
|
|
|
|
Disease Characterization: Are Biomarkers Better?
Presented By: Brian F. Chapin, MD
|
|
|
|
|
Disease Characterisation: MRI in Evaluation After Neoadjuvant Chemotherapy
Presented By: Andrea Necchi, MD
|
|
|
|
|
| Rapid-Fire Debates: Common Problems and Controversies in Bladder Cancer - 10:45-12:45 AM |
|
|
|
|
Is There Any Role for Urinary Markers Other than Cytology in Era of Modern Cystoscopy in Surveillance of Patients? What About to Decrease Frequency of Cystoscopy?
Presented By: Joan Palou MD, PhD, FEBU, FRCS (Glas), Eva Compérat, M.D., Ph.D., Tahlita Zuiverloon MD, Ph.D.
|
|
|
|
|
How Do We Manage a Patient with Frequent Recurrence of LG Papillary Tumours in the Bladder Despite Intravesical Chemotherapy and BCG Therapy? No Clinical Trial Available
Presented By: Marek Babjuk, CSc, Kenneth Chen, MBBS, MCI, MRCS (Edin) FRCS (Glas) FAMS, Philippe Spiess, MD
|
|
|
|
|
Healthy Patient with T1HG Micropapillary NMIBC - What Is the Best Treatment Option? What If Mixed Histologic Subtypes in Addition to Micropapillary?
Presented By: Paolo Gontero, MD, Benjamin Pradere, MD, MSc, Ashish Kamat, MD, MBBS
|
|
|
|
|
Patient with MIBC After Radical Cystectomy – Can We Use ctDNA to Guide Decisions on Adjuvant chemo/IO? What About utDNA for Bladder Sparing After NAC?Presented By: Andrea Necchi, MD, Peter Black, MD, FACS, FRCSC, Jørgen Bjerggaard Jensen, MD, DMSc
The Age-Old Debate – What Is the Best Treatment – Oncological and QOL – for Young Healthy Patient with MIBC? What About Health Care Related Costs?
Presented By: Fred Witjes, MD, Alison J. Birtle, FRCP, FRCR, MD, James Catto, MB, ChB, Ph.D., FRCS(Urol)
|
|
|
|
|
|
|
|
Patient with Non-Invasive, High-Grade Upper Tract Disease in Setting of Prior Radical Cystectomy – What Is Optimal Management? What If GFR ~ 50 Instead of 80?
Presented By: Morgan Rouprêt, MD, Ph.D., Sarah P. Psutka, MD, MSc, Arnulf Stenzl, MD
|
|
|
|
|
|
|
| Plenary Session: Risk-Adapted Screening and Treatment of Screen-Detected Prostate Cancer - 8:00-10:00 AM |
|
|
|
|
MRI Only (ReImagine Trial - UK Prostate Health Check)
Presented By: Caroline Moore
|
|
|
|
|
PSA Only (PROBASE - The German Screening Trial in Young Men)
Presented By: Boris Hadaschik, MD
|
|
|
|
|
PSA + MRI (OPT - The Swedish Nationwide Screening Strategy)
Presented By: Jonas Hugosson, MD, Ph.D.
|
|
|
|
|
PSA + Risk Calculators + MRI (The EAU Screening Algorithm)
Presented By: Katharina Beyer, MD
PSA + Blood-Based Biomarkers + MRI (ProScreen - The Finish Screening Trial)
Presented By: Anssi Auvinen, MD, Ph.D.
PSA+MRI+Targeted Biopsies Only (Gothenburg-2 Trial)
Presented By: Jonas Hugosson, MD, Ph.D.
Familial Prostate Cancer: Does It Influence the Screening and Management?
Presented By: Alicia Morgans, MD, MPH
|
|
|
|
|
|
|
|
| Plenary Session: Personalised Approaches in High-Risk and Metastatic Prostate Cancer - 08:00-10:00 AM |
|
|
|
|
State-of-the-Art Lecture Staging High-Risk Prostate Cancer with PET PSMA: Strengths and Pitfalls
Presented By: Irene Burger, MD
|
|
|
|
|
State-of-the-Art Lecture How to Personalise Treatment in mHSPca? More than Just Counting Metastases
Presented By: Karim Fizazi, MD, Ph.D.
|
|
|
|
|
State-of-the-Art Lecture Local Therapy in mHSPCa: Who Does Really Benefit?
Presented By: Alberto Bossi, MD
|
|
|
|
|
| Abstract Session 28: Basic Research and Trials - Non-Muscle Invasive Bladder Cancer - 13:45-15:15 PM |
|
|
|
|
Efficacy of Intravesical Nadofaragene Firadenovec-Vncg for Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: 36-Month Follow-up from a Phase 3 Trial
Presented By: Colin P. N. Dinney, M
|
|
|
|
|
| Abstract Session 31: Metastatic Prostate Cancer - 15:30 - 1700 PM |
|
|
|
|
A0647: Efficacy and Safety of Darolutamide in Combination with Androgen-Deprivation Therapy and Docetaxel in European Patients from the Phase 3 ARASENS Trial
Presented By: Bertrand Tombal, MD, Ph.D.
|
|
|
|
|
| Trials in Progress - 18:00 - 18:15 PM |
|
|
|
|
A Phase II Clinical Trial of Neoadjuvant Sasanlimab and Stereotactic Body Radiation Therapy as an in Situ Vaccine for Cisplatin Ineligible Muscle Invasive Bladder Cancer
Presented By: Raj Satkunasivam, MD, MS, FRCSC
|
|
|
|
|
|
|
| Plenary Session: Living with Advanced Kidney Cancer and Urothelial Cancer - 08:00-10:00 AM |
|
|
|
|
State-of-the-Art Lecture Advancements in Cutting-Edge SBRT Therapy for Oligometastatic Kidney Cancer
Presented By: Shankar Siva, Ph.D., MBBS, FRANZCR
|
|
|
|
|
| State-of-the-Art Lecture New Standard Treatment for Metastatic Bladder Cancer Based on EV-302/KEYNOTE-A39?Presented By: Andrea Necchi, MD
|
|
|
|
|
| Abstract Session 58: Surgical, Non-Surgical and Systemic Treatment of Localised Muscle-Invasive Bladder Cancer - 11:00 AM - 12:30 PM |
|
|
|
|
A0901: First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab (NIVO) and Nab-Paclitaxel (ABX) Followed by Postsurgical Adjuvant NIVO in Patients (Pts) with Muscle-Invasive Bladder Cancer (MIBC)
Presented By: Carissa Cicchinelli, MD
|
|
|
|
|
| Abstract Session 46: NMIBC: From Diagnosis to Prognosis - 12:30-14:00 PM |
|
|
|
|
A1032: A Prospective, Comparative, Within-Patient Controlled Multicenter Phase III Study Comparing Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer Using Modern HD 4K Equipment
Presented By: Hailong Hu, MD
|
|
|
|
|
A1027: Photodynamic Diagnosis (PDD) Directed Biopsies vs White Light Bladder Mapping in Patients with Positive Cytology and Negative Preoperative Workup: An International Multicenter Retrospective Study on Behalf of the European Association of Urology Young Academic Urologist Urothelial Working Group
Presented By: Francesco Colucci, MD, Ph.D.
|
|
|
|
|
|
